Eglumegad (LY354740) is a research drug developed by Eli Lilly and Company which is being investigated for its potential in the treatment of anxiety and drug addiction. It is a glutamate derived compound and its mode of action implies a novel mechanism.
This page contains content from the copyrighted Wikipedia article "Eglumegad"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
